INX IMCD N.V.

IMCD reports 11% EBITA growth in the first three months of 2020

IMCD reports 11% EBITA growth in the first three months of 2020

Rotterdam, The Netherlands (20 April 2020) - IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and food ingredients, today announces its first three months 2020 results and announces that its Annual General Meeting of Shareholders will be held on 30 June 2020. The AGM agenda will be published on 19 May 2020. 

HIGHLIGHTS

  • Gross profit growth of 12% to EUR 176.4 million (+12% on a constant currency basis)
  • Operating EBITA increase of 11% to EUR 70.9 million (+11% on a constant currency basis)
  • Net result before amortisation and non-recurring items increase of 13% to EUR 50.2 million (+13% on a constant currency basis)
  • Cash earnings per share increased by 13% to EUR 0.94 (first three months of 2019: EUR 0.83)

Piet van der Slikke, CEO: "IMCD's first quarter results were strong with an operating EBITA increase in all regions, overall with 11% to EUR 70.9 million. In this extraordinary time, we are fortunate to be able to rely on our excellent staff and strong commercial relationships for the continuation of our business. Whilst adapting working practices to safeguard the health of our employees and business partners, we have been able to remain open for business, even in cases of severe lock-down restrictions. However, with the duration of the COVID-19 crisis still unpredictable and the severity of its effect on the global economy yet unknown, it is difficult to quantify how it will impact our results in the months to come. We are nonetheless confident that IMCD's resilient business model and strong financial position will enable us to continue to pursue opportunities for future growth."

Please find attached the full press release.



Attachment

EN
20/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMCD N.V.

IMCD NV: 1 director

A director at IMCD NV bought 840 shares at 118.690EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

Guy Sips ... (+6)
  • Guy Sips
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi

Morning Notes : AALB NA, AD NA, ARCAD NA, SMAR BB, WKL NA, AZE BB, CTP...

: AALB NA, AD NA, ARCAD NA, SMAR BB, WKL NA, AZE BB, CTPNV NA, IMCD NA

Thibault Leneeuw
  • Thibault Leneeuw

IMCD Short-term revisions in light of the uncertainty

In this note we adjust our numbers to reflect the increased uncertainty which results in lower organic growth for FY25 and FY26. While the Gross Profit margin remained robust, OpEx was well above expectations across all regions. Due to these dynamics we lower our forecasted FY25 EBITA by 6% to € 548m. Furthermore, we dive into the divergence with Azelis as this stood out in 1Q25. Our adjustments result in a lower valuation of € 147 per share. Given the upside we maintain our Accumulate recommend...

 PRESS RELEASE

Shareholders IMCD N.V. adopt all resolutions at AGM

Shareholders IMCD N.V. adopt all resolutions at AGM Rotterdam, The Netherlands (25 April 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, announces that all resolutions proposed to the shareholders at the Annual General Meeting of Shareholders (AGM) held today were adopted. The resolutions included the adoption of the financial statements for the year 2024 and the proposal of a cash dividend of EUR 2.15 per share. The dividend calendar is as follows: 29 April 2025                Ex-dividend dat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch